{"Q": 1, "answer": "no", "rationale": "The segment does not contain an intensifier or comparative adjective directly modifying a risk-adjective.", "method": "llm_batch", "batch_id": "batch_1_20384", "batch_size": 200, "batch_pos": 86, "statement_text": "Moderna's mRNA vaccine research actually began with pandemic flu, and was modified for COVID, said Raffael Nachbagauer, executive director of infectious diseases at Moderna.", "article_id": 1272}
{"Q": 2, "answer": "no", "rationale": "The segment uses neutral language without high-potency verbs, metaphors, superlatives, intensifiers, or alert phrases.", "method": "llm_batch", "batch_id": "batch_2_19624", "batch_size": 200, "batch_pos": 65, "statement_text": "Moderna's mRNA vaccine research actually began with pandemic flu, and was modified for COVID, said Raffael Nachbagauer, executive director of infectious diseases at Moderna.", "article_id": 1272}
{"Q": 3, "answer": "no", "rationale": "The segment does not contain a moderate verb paired with explicit scale or impact information.", "method": "llm_batch", "batch_id": "batch_3_17060", "batch_size": 200, "batch_pos": 184, "statement_text": "Moderna's mRNA vaccine research actually began with pandemic flu, and was modified for COVID, said Raffael Nachbagauer, executive director of infectious diseases at Moderna.", "article_id": 1272}
{"Q": 4, "answer": "no", "rationale": "Segment does not contain a question.", "method": "llm_batch", "batch_id": "batch_4_17640", "batch_size": 200, "batch_pos": 173, "statement_text": "Moderna's mRNA vaccine research actually began with pandemic flu, and was modified for COVID, said Raffael Nachbagauer, executive director of infectious diseases at Moderna.", "article_id": 1272}
{"Q": 5, "answer": "no", "rationale": "Reports historical context without explicit calming language.", "method": "llm_batch", "batch_id": "batch_5_15152", "batch_size": 200, "batch_pos": 171, "statement_text": "Moderna's mRNA vaccine research actually began with pandemic flu, and was modified for COVID, said Raffael Nachbagauer, executive director of infectious diseases at Moderna.", "article_id": 1272}
{"Q": 6, "answer": "no", "rationale": "The segment does not contain a minimiser word or an explicit scale contrast.", "method": "llm_batch", "batch_id": "batch_6_19768", "batch_size": 200, "batch_pos": 132, "statement_text": "Moderna's mRNA vaccine research actually began with pandemic flu, and was modified for COVID, said Raffael Nachbagauer, executive director of infectious diseases at Moderna.", "article_id": 1272}
{"Q": 7, "answer": "no", "rationale": "The segment does not contain a bare negation.", "method": "llm_batch", "batch_id": "batch_7_19280", "batch_size": 200, "batch_pos": 120, "statement_text": "Moderna's mRNA vaccine research actually began with pandemic flu, and was modified for COVID, said Raffael Nachbagauer, executive director of infectious diseases at Moderna.", "article_id": 1272}
{"Q": 8, "answer": "yes", "rationale": "Describes past research/development, relating to capability/development without explicit calming keywords.", "method": "llm_batch", "batch_id": "batch_8_18756", "batch_size": 200, "batch_pos": 163, "statement_text": "Moderna's mRNA vaccine research actually began with pandemic flu, and was modified for COVID, said Raffael Nachbagauer, executive director of infectious diseases at Moderna.", "article_id": 1272}
